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Abstract
Oxidative damage is implicated in the pathogenesis of age-related macular degeneration
(AMD). The dry form of AMD (geographic atrophy) is characterized by loss of RPE, photoreceptors, and macular pigments. The cumulative effects of oxidative stress impact mitochondrial
function in RPE. In Sod2flox/floxVMD2-cre mice, the RPE specific deletion of Sod2, the gene for
mitochondrial manganese superoxide dismutase (MnSOD), leads to elevated oxidative stress
in retina and RPE, and causes changes in the RPE and underlying Bruch’s membrane that
share some features of AMD. This study tested the hypothesis that zeaxanthin supplementation
would reduce oxidative stress and preserve RPE structure and function in these mice. Zeaxanthin in retina/RPE/choroid and liver was quantified by LC/MS, retinal function and structure were
evaluated by electroretinogram (ERG) and spectral domain optical coherence tomography (SDOCT), and antioxidant gene expression was measured by RT-PCR. After one month of supplementation, zeaxanthin levels were 5-fold higher in the retina/RPE/choroid and 12-fold higher in
liver than in unsupplemented control mice. After four months of supplementation, amplitudes of
the ERG a-wave (function of rod photoreceptors) and b-wave (function of the inner retina) were
not different in supplemented and control mice. In contrast, the c-wave amplitude (a measure of
RPE function) was 28% higher in supplemented mice than in control mice. Higher RPE/choroid
expression of antioxidant genes (Cat, Gstm1, Hmox1, Nqo1) and scaffolding protein Sqstm1
were found in supplemented mice than in unsupplemented controls. Reduced nitrotyrosine content in the RPE/choroid was demonstrated by ELISA. Preliminary assessment of retinal ultrastructure indicated that supplementation supported better preservation of RPE structure with
more compact basal infoldings and intact mitochondria. We conclude that daily zeaxanthin supplementation protected RPE cells from mitochondrial oxidative stress associated with deficiency
in the MnSOD and thereby improved RPE function early in the disease course.
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Introduction
Age-related macular degeneration (AMD) is a leading causes of irreversible vision loss among
older adults. More than 11 million American have some form of AMD, and this number is
expected to increase substantially by 2050 [1]. Advanced AMD is typically manifested as choroidal neovascularization (wet AMD) or as geographic atrophy, referring to the progressive
death of RPE and photoreceptor cells in the macula (dry AMD) [2], both types cause significant loss of vision. Treatments targeting vascular endothelial growth factor (VEGF) are available for neovascular AMD, but effective treatment for geographic atrophy is urgently needed.
Retinal pigment epithelial (RPE) cells provide essential functions to support photoreceptors, including transport of nutrients and oxygen from the choroid to photoreceptors, phagocytosis of photoreceptor outer segments, and recycling of 11-cis-retinal, as part of the visual
cycle [3]. Early AMD is characterized by drusen—yellow deposits of oxidized lipids and protein that lie beneath the RPE layer in the macular region. Geographic atrophy in advanced
dry-AMD is a well-defined progressively enlarging area where photoreceptors, RPE and the
underlying choriocapillaris have been lost. While genetic risk factors for AMD connect dysregulation of the alternative complement cascade with AMD [4], the presence of oxidatively
damaged biomolecules in the RPE from AMD eyes [5–7] and ability of antioxidants in the
AREDS formulas to reduce risk for progression to advanced AMD [8] implicate oxidative
stress as a contributing factor. In fact, oxidized lipids and fragments of oxidized docashexaenoates activate complement and induce neovascularization in animal models [9–11]. Oxygen
consumption by the central retina is very high, and the metabolic demands necessary for the
RPE to serve photoreceptor needs are also substantial [12]. Under normal conditions, mitochondrial electron transport generates reactive oxygen species at complexes I and III, and
superoxide production may increase with age[13]. MnSOD in the mitochondria protects
against oxidative damage to critical molecules [14–15].
The importance of oxidative stress in this disease is reflected by the fact that smoking is secondary only to age as a risk factor for AMD [16]. Another indication that oxidative stress contributes to AMD comes from finding that dietary intervention with antioxidants retards the
progression of the disease. The Age-Related Eye Disease Study (AREDS) formulation (which contains vitamins C and E, beta-carotene and zinc) lowered risk of progression to advanced neovascular AMD, confirming the role of oxidative stress in AMD [17–18]. Of the 20+ carotenoids in
the diet, only two, lutein and zeaxanthin are accumulated in the retina as the macular pigment.
Meso-zeaxanthin, an isomeric metabolite of lutein, also accumulates [19–23]. Xanthophylls (lutein
and zeaxanthin) and n–3 fatty acids are essential for the development and maintenance of a normal distribution of RPE cells [24]. AREDS II determined that anti-oxidant supplements including
lutein and zeaxanthin reduced progression to advanced AMD with choroidal neovascularization
and that lutein and zeaxanthin may be superior to supplements containing beta-carotene, because
of the increased cancer risk of beta-carotene among smokers [8, 25]. Reduced risk for progression
to geographic atrophy has been associated with greater consumption of omega-3 long-chain polyunsaturated fatty acids [26], which are essential for the photoreceptors.
Consequently, supplementing the diet with higher levels of dietary lutein or zeaxanthin to
improve antioxidant protection in RPE could be a strategy to reduce or prevent progression of
early AMD to geographic atrophy. Zeaxanthin, a plant-derived antioxidant has been shown to
decrease oxidative stress markers and enhance antioxidant capacity in cultured cells [27]. Dorey
et al., found that zeaxanthin supplementation produced a dose-dependent increase in retinal zeaxanthin, and prevented light-induced photoreceptor cell death in quail [28–30]. Several studies
have shown antioxidants protect photoreceptors in vivo[31] and RPE cells in vitro [32–33]. Zeaxanthin and vitamin E protect phagocytic activity in RPE cells by reducing reactive oxygen species

PLOS ONE | https://doi.org/10.1371/journal.pone.0203816 September 28, 2018

2 / 16

Zeaxanthin prevents RPE atrophy

caused by light-irradiated lipofuscin [34]. We previously reported that elevated mitochondrial oxidative stress caused RPE dysfunction, damage to the choroid, and death of photoreceptor cells in
a mouse model [35]. We therefore hypothesized that dietary zeaxanthin would modulate RPE
atrophy due to oxidative stress resulting from MnSOD deletion in this model.
In this study, we tested the potential for daily zeaxanthin supplements to protect RPE cells
in Sod2flox/floxVMD2-cre mice in which the RPE-specific deletion of Sod2—the gene for manganese superoxide dismutase (MnSOD)—leads to elevated oxidative stress and RPE dysfunction
[35]. We detected increased zeaxanthin in retina/RPE/choroid and liver, increased expression
of antioxidant genes of the Nrf2 pathway in the retina/RPE, reduced RPE thinning and preserved RPE function compared with unsupplemented Sod2flox/floxVMD2-cre mice. Our results
indicate that dietary zeaxanthin supplementation prevents oxidative stress in RPE, identify
zeaxanthin supplementation as a way to protect RPE functions and point to its possible potential to reduce the risk for progression to dry AMD.

Materials and methods
Animals
All experimental procedures involving animals were performed according to the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research with the approval of the
Institutional Animal Care and Use Committee at the University of Florida. Sod2flox/floxVMD2-cre mice were transgenic for PVMD2-rtTA and tetO-PhCMV cre and were homozygous for Sod2 containing loxP sites surrounding exon 3, which encodes the manganese binding
site of superoxide dismutase. In these mice, only treatment with doxycycline activates cre
recombinase and that leads to Sod2 deletion only in the RPE due to cre expression driven by
the RPE specific VMD2 promoter [36]. Two month old (male and female) mice were chosen
for zeaxanthin treatment experiments. The mice were housed in a controlled environment at
20–24˚C under pathogen-free conditions with a 12-h light-dark cycle and ad libitum access to
food and water. Expression of the cre transgene was induced in neonatal mice by feeding nursing dams doxycycline-containing chow (200 mg/kg rodent diet [T-7012, 200 doxycycline];
Harlan Laboratories, Inc., Tampa, FL, USA) for 2 weeks immediately after the birth of the litter
[35]. Importantly, doxycycline treatment was completed more than three months before measurement of oxidative injury or retinal function.

Zeaxanthin treatment
Zeaxanthin encapsulated beadlets having 5% zeaxanthin were provided by EyePromise (Chesterfield, MO). These beadlets were mixed with water at a concentration of 150 mg/ml (containing 7.5 mg/ml zeaxanthin), and 150μl to 200μl of the dissolved beadlets were delivered to 20 to
25 gm Sod2flox/flox-VMD2-cre mice (n = 12) for four months. Each mouse received a daily dosage of 55 to 60mg/kg of zeaxanthin through beadlets (1.125 mg of zeaxanthin for a 20gm
mouse). A separate sham control group of Sod2flox/flox-VMD2-cre mice (n = 8) received no zeaxanthin and were housed with the treated mice and handled similarly on a daily basis. At the
end of experiments, mice were euthanized either by inhalation of carbon dioxide (>90%) for
biochemical studies or by injection of 150 mg/kg of sodium pentobarbital (as Euthasol™) for
electron microscopy studies.

Analysis of zeaxanthin concentration
Tissues were collected and snap frozen for zeaxanthin quantification by HPLC at Craft Technologies, Inc. (Wilson, NC) as described in detail by Toyoda et al. [30].
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Electroretinography
For electoretinography (ERG), mice were dark-adapted overnight. Prior to injection of anesthesia, the eyes were dilated twice (10–15 min apart) with one drop each of 2.5% phenylephrine hydrochloride ophthalmic solution (Paragon BioTek, Inc., Portland, OR) and 1%
atropine sulfate ophthalmic solution (Akorn, Inc., Lake Forest, IL). The mice were anesthetized with a mixture of ketamine (95 mg/kg) and xylazine (5–10 mg/kg) by intraperitoneal
injection. Prior to placing electrodes to record ERG, one drop of sterile lubricant eye drops
(CVS Pharmacy, Inc., Woonsocket, RI) was applied to each of the eyes to prevent the eye from
drying during procedures. To examine retinal responses, scotopic a-, b- and c-wave amplitudes from each eye were measured using Espion full-field ERG system (Diagnosys LLC, Lowell, MA 01851) at a flash intensity of 20 cds/m2) [37]; the results from treated and untreated
eyes were compared.

Spectral-Domain Optical Coherence Tomography (SD-OCT)
Eyes were dilated, and mice were anesthetized as described above for ERG analysis, High-resolution SD-OCT images were obtained by employing Envisu SD-OCT ophthalmic imaging system (Leica/Bioptigen, Durham, NC, USA) as described in our previous paper [38].
Photoreceptor survival was assessed by measuring the thicknesses of the outer nuclear layer
(ONL) at four different locations (temporal, nasal, superior, and inferior) at 0.35-mm distance
from the optic nerve head (ONH). Upon averaging the ONL thickness measurements from
both the left and right eye, the results were compared between treated and untreated mice.

Relative quantification of mRNA expression of antioxidant genes
The retina and RPE/choroid were dissected and collected in RNA later stabilization solution
(ThermoScientific). Total RNA was isolated using the RNeasy mini kit (Qiagen), and first
strand cDNA for each sample was generated using 500ng of total RNA (iScript from Biorad).
Using universal SYBR Green Supermix (Biorad), primers for the mouse antioxidant genes catalase (Cat), glutathione S-transferase Mu 1 (Gstm1), heme oxygenase 1 (Hmox1), NAD(P)H
quinone dehydrogenase 1 (Nqo1), and sequestosome 1 (Sqstm1) were designed using the
NCBI primer database to amplify 200bp amplicons for each gene (S1 Table). Real Time-PCR
amplification was performed using CFX manager (Biorad). Target genes were assayed with
glyceraldehyde 3-phosphate dehydrogenase (Gapdh) for standardization. All reactions were
performed in triplicate, and the average relative threshold cycle (ΔΔCt) from each sample was
recorded for data analysis. The change in expression of each gene was determined relative to
control mice after normalization to Gapdh.

Evaluation of oxidative stress marker (Nitrotyrosine) by ELISA
RPE/choroid and retina from each sample were collected separately in phosphate buffered
saline (PBS) with protease inhibitors (Thermo Fisher Scientific) and homogenized using manual homogenizer. The homogenate was centrifuged at 12,000 RPM for 30 minutes at 4˚C, and
the supernatant of tissue lysate was collected for ELISA. Each animal was assayed in triplicate
and averaged to obtain a single data point; three animals per group were analyzed. The nitrotyrosine (3-nitrotyrosine, 3NT) competitive enzyme-linked immunosorbent assay (ELISA)
(Abcam) was used to estimate the nitrotyrosine-modified protein levels from the retina/RPE/
choroid sample, performed according to the manufacturer’s protocol.
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Light and electron microscopy
After the overdose of sodium pentobarbital, mice were perfused with PBS containing 2% paraformaldehyde and 2.5% glutaraldehyde and the eyes were collected in the above mixture for
light and electron microscopy. The eyes were processed according to the procedure described
in our previous paper [35].

Statistical analysis
The statistical software GraphPad Prism (version 5.0; Graph Pad Software, Inc., San Diego,
CA, USA) was used to analyze the data. All reported P values were calculated using the 2-tailed
Mann-Whitney test as indicated in the legends and a P value of <0.05 was considered significant. All data are represented as mean ± SEM unless otherwise indicated.

Results
Zeaxanthin supplementation leads to accumulation in liver and retina/
RPE/choroid
After one month, the mean concentration of zeaxanthin in livers from experimental mice was
12 times higher than that in unsupplemented control mice (210.0 ± 15.7ng/gm (n = 3) vs
17 ± 5.44 ng/gm (n = 3); P<0.0010.003). Zeaxanthin concentration in the retina/RPE/choroid
was 5-fold higher in supplemented mice (12.6 ± 1.8 ng/gm, n = 4) than in control mice
(2.3 ± 0.8 ng/gm, n = 3); P<0.01 (Fig 1). Because the mouse retina expresses a carotenoid
cleavage enzyme (β,β-carotene-9’,10’-dioxygenase)[39], we suspect that zeaxanthin increased
primarily in the RPE, but we have not yet validated this by analyzing zeaxanthin in dissected
RPE.

Zeaxanthin treatment changed antioxidant gene expression in RPE
After one month and four months of gavage, the retina and RPE/choroid samples were harvested for quantitative real-time PCR analysis to measure levels of antioxidant response element regulated antioxidant transcripts, which are under the control of the Nrf2 (NFE2L2)
transcriptional factor. No significant changes in antioxidant gene expression were seen after
one-month of treatment (Fig 2A and 2B). At four months, the supplemented mice had more

Fig 1. Zeaxanthin retention. The experimental group (n = 3) received daily gavage feeding of zeaxanthin beadlet at a
dosage of 55-60mg/kg body weight for one month resulted in 12-fold retention of zeaxanthin in liver (n = 3) (A) and
5-fold retention in retina/RPE/choroid (n = 4) (B) compared to control untreated group (n = 3) on normal diet
(Unpaired t-test, two tailed  P<0.01 and  P <0.001).
https://doi.org/10.1371/journal.pone.0203816.g001
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Fig 2. Zeaxanthin induces antioxidant response in the RPE. An experimental group (n = 5) receiving daily gavage
feeding of zeaxanthin for one month did not exhibit induction of antioxidant genes such as Catalase (Cat), Glutathione
S-Transferase Mu 1 (Gstm1), Heme Oxygenase 1 (Hmox1), NAD(P)H Quinone Dehydrogenase 1 (Nqo1), and
Sequestosome 1 (Sqstm1) in RPE/choroid (A) or retina (B) compared to control group (n = 5). However, after four
months of supplementation, the experimental group had greater mRNA expression of the antioxidant enzymes in the
RPE/choroid (N = 5:P<0.05) than the control group (N = 5) (C); expression in the retina (D) was not affected by
supplementation.
https://doi.org/10.1371/journal.pone.0203816.g002

than 3-fold higher levels of Cat, Gstm1, Hmox-1, Nqo-1 and Sqstm1 mRNA in the RPE/choroid
(Fig 2C). There was no change in gene expression in the neural retina (Fig 2D).

Reduction of protein nitration in RPE
Tyrosine nitration arises from modification of tyrosine residues by peroxynitrite (ONOO-)
formed from the reaction of superoxide (O2-.) with nitric oxide (NO). We previously reported
that Sod2 deletion in the RPE resulted in higher RPE concentrations of nitrotyrosine [37–38].
Zeaxanthin supplemented mice had 60% lower levels of nitrotyrosine (2.03±0.25 μg/mg, n = 6)
in the RPE than the controls (5.0±1.3 μg/mg, n = 3; P = 0.015)(Fig 3A); but supplementation
had no effect (P = 0.63) on nitrotyrosine concentration in the neural retina (2.15 ±0.3 μg/mg,
n = 7 vs 2.0±0.16 μg/mg, n = 3) (Fig 3B).

Improved c-wave ERG as a measure of RPE function
Electroretinography detects electrical responses of the retina to light flashes. The a-wave arises
from photoreceptor cells, whereas the larger b-wave is the result of subsequent bipolar cell
activity. The c-wave derives from the response of RPE to reduced potassium ion concentrations in the interphotoreceptor space during illumination [40]. As anticipated, there was a
decrease in a-wave (from 73.4 ± 5.5, n = 8 to 44.8 ± 5.7, n = 8; P = 0.002) and b-wave (from
162.9 ± 13.4, n = 8 to 12.0 ± 11.6, n = 8; P = 0.01) amplitudes in control mice at 6 months of
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Fig 3. Reduced protein nitrosylation in the RPE following zeaxanthin treatment. In response to zeaxanthin
treatment for 4 months, Sod2flox/floxVMD2-cre mice (n = 5) at 6 months of age showed a reduced level of nitrotyrosine
in the RPE/choroid (A) but not in the retina where levels were already low (B) compared to eyes from untreated
control Sod2flox/floxVMD2-cre mice (n = 5) by ELISA ( P < 0.5).
https://doi.org/10.1371/journal.pone.0203816.g003

age compared to 4 months of age (Fig 4A and 4B). After 4 months of supplementation, comparison of ERG’s in supplemented and control mice at 6 months of age showed no significant
difference in the a-wave (52.3 ± 4.1 n = 11 vs 44.8 ± 5.7, n = 8; P = 0.3) or b-wave (116.8 ± 11.4,
n = 11 vs 112.0 ± 11.7, n = 8; P = 0.7) amplitudes. In our earlier characterization of this model,
we found significant decline in the a-wave and b-wave responses in Sod2flox/flox-VMD2-cre
mice only after six months of age [35]. In untreated mice, the c-wave amplitudes were lower at
6 months of age compared to 4 months of age. However, in the case of the c-wave we did
observe benefit from zeaxanthin treatment. Even though the c-wave amplitude declined in the
control group, the average c-wave amplitude (249.9 ± 12.1 μV, n = 11) in the supplemented
mice did not decline between 4 months of age and 6 months of age. At both ages, the c-wave
amplitudes in zeaxanthin supplemented mice were significantly higher than in control mice
(Fig 4C). Representative ERG wave forms after 4 months of treatment are illustrated in S1 Fig.

Fig 4. Improvement of RPE function detected by electroretinography. Dark-adapted electroretinogram (ERG) amplitudes
measured at a light intensity of 20 cds/m2 at 4 months (4mo) and 6 months (6mo) of age after initiation of zeaxanthin treatment at
2 months of age. In the untreated group (n = 8), significant changes in (A) a-wave, (B) b-wave and (C) c-wave amplitudes were
noticed at 6 months of age compared to 4 months of age. Daily gavage feeding of zeaxanthin did not result in any significant
change in (A) a-wave and (B) b-wave amplitudes between control (n = 8) and zeaxanthin treated mice (n = 11) at 6 months (6mo)
of age (4 months after onset of treatment). However, zeaxanthin fed Sod2flox/flox VMD2-cre (C) mice had greater c-wave amplitudes
at 6 months (6mo) of age (4 months after onset of treatment) than did the untreated Sod2flox/floxVMD2-cre mice at 6 months (6mo)
of age following flashes of same light intensity ( P<0.01).
https://doi.org/10.1371/journal.pone.0203816.g004

PLOS ONE | https://doi.org/10.1371/journal.pone.0203816 September 28, 2018

7 / 16

Zeaxanthin prevents RPE atrophy

Fig 5. Zeaxanthin treatment improved structure of photoreceptor outer segments and the RPE. SD-OCT image of retinas from
the zeaxanthin treated groups (n = 11) (B) after four months of treatment (6 months of age) shows preserved RPE layer and outer
segment layer compared to eyes from untreated mice (n = 8) (A) of same age. We did not see any significant change in retinal outer
nuclear layer (ONL) thickness (C) between control untreated and zeaxanthin-treated group. The red arrow indicates the RPE layer
and the green arrow indicates the region of the photoreceptor outer segments.
https://doi.org/10.1371/journal.pone.0203816.g005

SD-OCT demonstrated improved RPE thickness
Spectral domain optical coherence tomography (SD-OCT) is a reflectance technique used to
measure the thickness of retinal layers and the accumulation of subretinal deposits [41]. In this
mouse model of RPE oxidative stress, we have previously observed decrease in the thickness of
the ONL at six months of age. After four months of treatment, SD-OCT examination detected
no difference in ONL thickness in zeaxanthin-fed and control mice (Fig 5). However, comparison of OCT B-scans of zeaxanthin-treated and control mice revealed that the zeaxanthin-supplemented mice had sharper definition of the photoreceptor and RPE layers, more clearly
resolved laminar structure, and reduced reflectance in outer nuclear layer (green arrows in Fig
5A and 5B).

Improved RPE fine structure
In light micrographs of 6-month old untreated mice, the RPE exhibited areas of reduced melanin
(white arrow head) and interrupted contact with photoreceptor outer segments (black arrow)
(Fig 6). Ultrastructural analysis of these untreated Sod2-deleted RPE revealed disorganized basal

Fig 6. Light micrograph analysis. Preliminary data showed increased melanosomes in the RPE layer in the zeaxanthin
treated eyes (n = 2) (B) compared to untreated eyes of same age (n = 2) (A). Both images are from the same location in
the posterior retina of each eye. (scale bar 100μm). In A, black the arrow indicates a region in which outer segments of
photoreceptors appear detached from the RPE and the white arrow head indicates a region of hypopigmentation in the
RPE.
https://doi.org/10.1371/journal.pone.0203816.g006
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Fig 7. Improved ultrastructure of RPE. Ultrastructure analysis showed preservation of photoreceptors and RPE in
the zeaxanthin treated eyes (n = 2) (B and D), whereas the eye from untreated mice (n = 2) (A and C) revealed broken
tips of photoreceptors outer segments. Mitochondria were visible in the treated RPE (black arrows in D) but were
sparse in the untreated eyes. The accumulation of lipofuscin granules (small black dots indicated by blue arrows in C)
were reduced in treated eyes. RPE of the untreated eye had visible nuclear alterations such as nuclear pyknosis whereas
the RPE cells in treated eyes had a normal, round nucleus (red arrow).
https://doi.org/10.1371/journal.pone.0203816.g007

in-foldings, almost no mitochondria, and pyknotic nuclei (Fig 7A and 7D). Photoreceptor outer
segments were poorly aligned and had broken tips as if phagocytosis of outer segments was
impaired. In zeaxanthin-supplemented mice (Fig 7B and 7D), RPE had more organized and compact basal in-foldings, rounded nuclei with more dispersed chromatin, and many mitochondria at
the basal surface, features typical of healthy RPE. Outer segments of photoreceptors were in parallel alignment, and no broken tips were apparent. Improved alignment of outer segments would
improve their wave guiding properties and reduce the reflectance seen in the OCT images of
unsupplemented mice.

Discussion
Dietary supplementation with zeaxanthin protected the RPE from the impact of mitochondrial
oxidative stress. Data presented here demonstrated that retention of zeaxanthin, presumably
in the RPE, reduced oxidative stress as measured by nitrotyrosine and prevented the degenerative changes in RPE observed in the unsupplemented Sod2 deficient mice.
Oxidative damage accumulating with age is a risk factor for age-related macular degeneration [42], and mitochondrial energy metabolism is a major source of reactive oxygen species.
There are few animal studies, however, demonstrating the retention of carotenoids in retina,
liver, and lens [28–30]. We, therefore, studied the effect of zeaxanthin supplementation in the
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Sod2flox/floxVMD2-cre mouse model of RPE-atrophy induced by chronic mitochondrial oxidative stress in RPE.
A recent clinical study involving combinational therapy showed that zeaxanthin did protect
the macula in already diseased eyes [43]. These studies in advanced AMD were different from
AREDS2 in that they used 10-fold higher (and putatively more effective) doses of zeaxanthin
(20 mg vs 2). Zeaxanthin supplements reduced progression of CNV development in the fellow
eye by 70–80%, and this was likely independent of the triple therapy to the contralateral eye
consisting of: (1) reduced-fluence photodynamic therapy with verteporfin, (2) intravitreal bevacizumab and (3) intravitreal dexamethasone. It is reasonable to consider that the additional
protection is associated with direct effects of zeaxanthin on the RPE. The rationale behind the
use of the zeaxanthin alone in our experiment was to detect possible effects attributable only to
carotenoid supplementation and its unique accumulation. In the future, it will be interesting
to study the effects of lutein vs zeaxanthin supplementation or combinational effects of zeaxanthin and lutein in the Sod2flox/floxVMD2-cre mouse model. We would also specifically measure
accumulation in isolated RPE.
Li and co-workers reported that wild-type C57BL/6 mice could not accumulate carotenoids
in the retina due to the presence of highly active β,β-carotene-9’,10’-dioxygenase (BCO2)
enzyme which is inactive in the human retina [39]. Inactivation of this activity resulted in the
accumulation of lutein and zeaxanthin in mouse retinas. Whether it was possible to bypass this
activity and achieve significant delivery to the retina by supplementing with super physiological levels of zeaxanthin was not known; while our data indicate zeaxanthin was delivered to the
RPE, we do not know whether the retina itself accumulated zeaxanthin. The zeaxanthin dose
we employed was not derived from a dose response curve, but was based on the average American dietary intake. There is no basis on which one could argue that it is the optimal dose. Prophylactic treatments are sometimes given at doses above the normal physiological range,
especially if it is known that the person is deficient in the normal uptake path. The rationale
for a high dose of zeaxanthin was to provide enough zeaxanthin to saturate the activity of
BCO2 and effectively deliver zeaxanthin to the mouse retina. In earlier work, zeaxanthin was
added directly to mouse diet at 1 gm of zeaxanthin/kg or ~7.5ng/kg if fed to 30 gm BALB/c
mice eating 4.5 grams of food per day [44]. We chose to give mice 1.15mg-1.5mg of zeaxanthin
for 20gm to 25gm of mice. This ended up being of 56.3 mg to 60 mg of zeaxanthin per kg body
weight of mice. The US Food and Drug Administration (Estimating the safe starting dose in
clinical trials for therapeutics in adult healthy volunteers, U.S. Food and Drug Administration,
Rockville, Maryland, USA) recommends that translation from human to animal dose should
be based on body surface area, not on weight [45]. By this calculation 60 mg/kg in a mouse corresponds to a daily dosage of 4.9 mg/kg in a 60 kg adult human. While this is higher than the
AEREDS2 recommendation, it is below the high dose tested in humans.
It would have been wise to measure the levels of zeaxanthin in the eye at multiple time
points and, in particular, at 4 months. We chose one month, because we wanted to be sure that
zeaxanthin was indeed accumulated despite the presence of β,β-carotene-9’,10’-dioxygenase
(BCO2) in the mouse retina. In other words, this time point was chosen to help us decide
whether to continue the treatment. The livers accumulated around 12 times more zeaxanthin
than control livers after one month. It is possible, and indeed likely, that zeaxanthin continued
to accumulate in the retina/RPE/choroid, but we did not measure accumulation after a longer
interval, and this is a shortcoming of our experiments. Uptake, metabolism, and stabilization
of xanthophyll carotenoids in the retina are thought to be mediated by specific xanthophyllbinding proteins (XBPs). The Pi isoform of human glutathione S-transferase (GSTP1) is a zeaxanthin-binding protein whose enzyme activity is increased when zeaxanthin is bound [46]. In
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our future studies; we aim to investigate GSTP1 protein expression in the RPE/choroid and
retina in response to zeaxanthin accumulation in the RPE.
The protection of structure and function of RPE raised questions about the mechanism of
protection. Zeaxanthin effectively protected against tert-butyl hydroperoxide-induced mitochondrial dysfunction and apoptosis in RPE cells through NF-E2-related factor 2 (NRF2) activation [27]. Zeaxanthin was further reported to protect a rat model of oxidative damage by
inducing NRF2 and HO-1 [47]. In Sod2flox/floxVMD2-cre mice we expected greater oxidative
stress in RPE since an essential antioxidant enzyme was deleted in the RPE. Our observation
that zeaxanthin increased RPE expression of NRF2 -regulated enzymes, including catalase,
NAD(P)H quinone dehydrogenase 1and heme oxygenase 1 confirmed the induction of antioxidant enzyme mechanism in vivo. The mu class of glutathione S-transferase (GSTM1) enzyme
functions in the detoxification of electrophilic compounds, and products of oxidative stress, by
conjugation with glutathione [48]. Dietary supplementation of zeaxanthin also increased
GSTM1 expression in Sod2flox/floxVMD2-cre mice. Since the ARE genes are regulated at the
stage of transcription, we presume that the protein levels also increased, but we did not confirm this using immunological methods. Zou et al. also showed that oral supplementation of
zeaxanthin induces Nrf2-mediated phase II enzymes in vitro and in vivo [27]. Not having the
protein data to support increased antioxidant defense by RPE is a weakness in the current
study and it will be explored in future studies.
Oxidative stress marker nitrotyrosine is produced by the modification of protein tyrosine
residues by peroxynitrite generated from the reaction of nitric oxide (NO) and superoxide.
Increased nitrotyrosine level in the retina was reported in the animal model of photoreceptor
oxidative damage [49] and aging human Bruch’s membrane [50]. We have reported significant
elevation of nitrotyrosine in Sod2flox/floxVMD2-cre mouse by 2 months of age [35] and that its
level was decreased in response to systemic treatment with a 5HT1a agonist [38]. Dietary supplementation of zeaxanthin led to significant reduction of nitrotyrosine level in RPE/choroid
(Fig 3). We did not find significant changes in nitrotyrosine levels in the retina of treated and
untreated mice, but nitrotyrosine levels were already low. The fact that the nitrotyrosine levels
were not affected in the retina indicates that the oxidative damage in the retina is due to local
generation of peroxynitrite, and further supports the view that zeaxanthin did not accumulate
in the retina of these mice. Free radicals are too short-lived to move from the RPE across the
subretinal space to the retina.
Supplementation with zeaxanthin did not support improvement in photoreceptor layer
thickness by SD-OCT, despite a 5-fold increase in zeaxanthin retention in the retina/RPE/choroid after one month of supplementation. We anticipated that increased zeaxanthin retention
in RPE would benefit retinal function as detected by ERG a- or b-wave responses after four
months of treatment. However, despite the preservation of RPE function, based on the c-wave
response and improved RPE ultrastructure in response to zeaxanthin treatment, we did not
see preservation of neural retina structure and function. In this model, initial RPE dysfunction
affects neural retina function secondarily. The fact that c-waves in 6 month old treated mice
are same as in 4 month old mice suggests that the implied retention of RPE functionality did
not benefit neural retina function. We suspect that the presence of BCO2 enzyme activity in
the retina prevented zeaxanthin accumulation in the retina, thus interrupting any antioxidant
protection or induction of antioxidant enzymes from RPE. However, for practical reasons, we
stopped our analysis before we expected the statistically significant reduction in ERG a-wave
and b-wave amplitudes or ONL thickness that we had previously shown [35]. The experiments
in Figs 6 and 7 had a very low n n = 2, and therefore are presented solely as preliminary data
encouraging the future work necessary to reach concrete conclusions. Protection of the RPE in
our experiments implies that zeaxanthin did accumulate in the RPE as confirmed by the
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induction of Nrf2-regulated enzymes, the preservation of RPE structural integrity, and the protection of RPE function as indicated by the preserved c-wave amplitude (Fig 4) and by the preserved ultrastructure of the RPE (Fig 7).

Conclusions
In our experiments, dietary zeaxanthin induced Nrf2-dependent antioxidant enzymes, thus
protecting RPE from oxidative induced damage and substantially preserved RPE structure and
function. Because oxidative stress in the RPE is implicated in age-related macular degeneration, we believe that daily intake of zeaxanthin may reduce the risk for development of AMD.
Further studies in BCO2 knockout mice are needed to assess whether elevating retinal zeaxanthin can retard RPE and photoreceptor atrophy. Additional questions to be addressed include
whether zeaxanthin supplementation could slow disease progression after retinal and/or RPE
degeneration is already initiated and whether this intervention could be useful in diseases in
which the primary insult does not involve RPE oxidative stress [51].
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